Cliff Asness's APGE Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 8,027 shares of Apogee Therapeutics, Inc. (APGE) worth $675,633, representing 0.00% of the portfolio. First purchased in 2024-Q2, this short-term holding has been held for 5 quarters.
Based on 13F filings, Cliff Asness has maintained this position in APGE for several quarters, showing initial confidence in the investment. Largest addition occurred in Q1 2026, adding 8,027 shares. Largest reduction occurred in Q3 2024, reducing 11,535 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's Apogee Therapeutics (APGE) Holding Value Over Time
Track share changes against reported price movement
Quarterly Apogee Therapeutics (APGE) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +8,027 | New Buy | 8,027 | $84.17 |
| Q1 2025 | -5,365 | Sold Out | 0 | $0.00 |
| Q4 2024 | +5,365 | New Buy | 5,365 | $45.30 |
| Q3 2024 | -11,535 | Sold Out | 0 | $0.00 |
| Q2 2024 | +11,535 | New Buy | 11,535 | $39.35 |
Cliff Asness's Apogee Therapeutics Investment FAQs
Cliff Asness first purchased Apogee Therapeutics, Inc. (APGE) in Q2 2024, acquiring 11,535 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held Apogee Therapeutics, Inc. (APGE) for 5 quarters since Q2 2024.
Cliff Asness's largest addition to Apogee Therapeutics, Inc. (APGE) was in Q2 2024, adding 11,535 shares worth $453,902.
According to the latest 13F filing for Q1 2026, Cliff Asness's firm, Aqr Capital Management LLC, owns 8,027 shares of Apogee Therapeutics, Inc. (APGE), valued at approximately $675,633.
As of the Q1 2026 filing, Apogee Therapeutics, Inc. (APGE) represents approximately 0.00% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in Apogee Therapeutics, Inc. (APGE) was 11,535 shares, as reported at the end of Q2 2024.